---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-044126"
form_type: "8-K"
ticker: "RNAZ"
cik: "0001829635"
company_name: "Transcode Therapeutics, Inc."
filed_at: "2025-05-02T23:59:59+00:00"
generated_at: "2026-05-22T23:03:37.459082+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# TransCode Therapeutics announces 1-for-28 reverse stock split to regain Nasdaq compliance

## Summary
- Stockholders approved 1-for-28 reverse split on May 2, 2025; board ratified the ratio.
- Outstanding shares will reduce from about 23.3M to approximately 833,620.
- No fractional shares issued; fractional shares rounded up to nearest whole share.
- Effective date to be announced at least two business days prior to implementation.
- Split designed to meet Nasdaq minimum bid price requirement for continued listing.

## SEC filing metadata
- accession: 0001104659-25-044126
- form_type: 8-K
- ticker: RNAZ
- cik: 0001829635
- company_name: Transcode Therapeutics, Inc.
- filed_at: 2025-05-02T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.07, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829635/000110465925044126/0001104659-25-044126-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829635/000110465925044126/tm2513881d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-044126
- JSON: https://secwatch.observer/filing/0001104659-25-044126.json
- Plain text: https://secwatch.observer/filing/0001104659-25-044126.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.